CYP4F62P

Across TCGA pan-cancer cohorts, CYP4F62P RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of CYP4F62P’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where CYP4F62P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CYP4F62P is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

BRCA, LUAD, and KICH are the cancer types where CYP4F62P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CYP4F62P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	+0.201	.009	4	view →
LUAD	Female	III,IV	−0.028	.014	4	view →
KICH	Male	II,III,IV	+0.022	.007	4	view →
PRAD	All	All	+0.647	<.001	2	view →
PAAD	Female	All	+0.350	.020	2	view →
BLCA	All	All	+0.010	.015	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

CYP4F62P–BRCA

Open the BRCA breakdown →